Midatech Pharma PLC Retirement of Chairman and Proposed New Chairman (3736O)
June 10 2022 - 2:01AM
UK Regulatory
TIDMMTPH
RNS Number : 3736O
Midatech Pharma PLC
10 June 2022
10 June 2022
Midatech Pharma PLC
("Midatech" or the "Company")
Retirement of Chairman and Proposed Appointment of New
Chairman
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D
biotechnology company focused on improving the bio-delivery and
biodistribution of medicines , announces that Rolf Stahel, Chairman
and non-executive director, intends to retire after the Company's
Annual General Meeting on 20 June 2022 ("AGM"). It is expected that
Dr. Stephen Parker will be appointed as non-executive Chairman of
the Board, following the AGM.
Stephen Parker has over 30 years' experience in leadership roles
both in the healthcare industry and in advisory roles. Currently,
he is Chairman of Sareum Holdings plc (AIM: SAR) and Drishti
Discoveries Ltd, a Non-Executive Director of MGC Pharmaceuticals
Ltd (LON: MXC) and an Executive Director of sp(2) Consulting
Limited. Previously, Stephen held a number of executive and board
positions at various public and private biotech companies and
senior roles at leading investment banks. Stephen has an MBA from
City University and a D.Phil. in biochemistry from Oxford
University.
Commenting, Stephen Stamp, CEO and CFO of Midatech, said: "On
behalf of all stakeholders I would like to thank Rolf for his
contribution to Midatech over the last seven years and, from a
personal perspective, for his leadership and counsel during my
tenure over the last two years. We wish him well in his much
deserved retirement. I should also like to welcome Stephen to the
Board. Stephen's broad experience both as an executive in, and
senior adviser to, the industry will be invaluable to Midatech in
the next stage of the Company's evolution. I am very much looking
forward to working with Stephen."
Commenting, Stephen Parker, said: "It is a great pleasure to be
proposed as a director, and Chairman, of Midatech, whose technology
base I have long admired. It is a particular privilege to be asked
to succeed Rolf Stahel and I join Stephen in thanking Rolf for his
leadership to date. I look forward to working with the Midatech
Board and team."
Commenting, Rolf Stahel, added: "I am handing over the Chairman
function to Stephen Parker whose proposed appointment has the
unanimous support from the directors of Midatech. I have full
confidence that Stephen Parker and Stephen Stamp, together with the
other non-executive directors will form a powerful team leading
Midatech to its promising future. I would like to thank all
stakeholders for the support I have received over the last seven
years."
For more information, please contact:
Midatech Pharma PLC
Stephen Stamp, CEO, CFO
Tel: +44 (0)29 20480 180
www.midatechpharma.com
Strand Hanson Limited (Nominated and Financial Adviser)
James Dance / Matthew Chandler / Rob Patrick
Tel: +44 (0)20 7409 3494
Turner Pope Investments (TPI) Limited (Joint Broker)
Andrew Thacker / James Pope
Tel: +44 (0)20 3657 0050
IFC Advisory Limited (Financial PR and UK Investor Relations)
Tim Metcalfe / Graham Herring
Tel: +44 (0)20 3934 6630
Email: midatech@investor-focus.co.uk
Edison Group (US Investor Relations)
Alyssa Factor
Tel: +1 (860) 573 9637
Email: afactor@edisongroup.com
About Midatech Pharma PLC
Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ:
MTP) is a drug delivery technology company focused on improving
the bio-delivery and bio-distribution of medicines . The Company
combines approved and development medications with its proprietary
and innovative drug delivery technologies, to provide compelling
products that have the potential to powerfully impact the lives
of patients.
The Company has developed three in-house technology platforms,
each with its own unique mechanism to improve delivery of medications
to sites of disease. All of the Company's technologies have successfully
entered human use in the clinic, providing important validation
of the potential for each platform:
* Q-Sphera(TM) platform: a disruptive micro-technology
used for sustained release to prolong and control the
release of therapeutics over an extended period of
time (from weeks to months).
* MidaSolve(TM) platform: an innovative nanotechnology
used to dissolve insoluble drugs so that they can be
administered in liquid form directly and locally into
tumours.
* MidaCore(TM) platform: a leading-edge nanotechnology
used for targeting medications to sites of disease.
The platform nature of the technologies offers the potential to
develop multiple drug assets rather than being reliant on a limited
number of programmes. Midatech's technologies are supported by
36 patent families including 120 granted patents and an additional
70 patent applications. Midatech's headquarters and R&D facility
is in Cardiff, UK. For more information please visit www.midatechpharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAFZGGVDLDGZZM
(END) Dow Jones Newswires
June 10, 2022 02:01 ET (06:01 GMT)
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Sep 2023 to Sep 2024
